Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

No existing drug provides the combined potential advantages of reducing vascular- and bronchial-constriction, and anti-inflammation. Vasoactive intestinal peptide (VIP) is widely expressed throughout the cardiopulmonary system and exerts a variety of biological actions, including potent vascular and airway dilatory actions, potent anti-inflammatory actions, improving blood circulation to the heart and lung, and modulation of airway secretions.

https://respiratory-research.biomedcentral.com/articles/10.1186/1465-9921-12-45

Worldwide increase incidences of allergic diseases have heightened the interest of clinicians and researchers to understand the role of neuroendocrine cells in the recruitment and activation of inflammatory cells. Several pieces of evidence revealed the association of neuropeptides in the pathogenesis of allergic diseases. Importantly, one such peptide that is secreted by neuronal cells and immune cells exerts a wide spectrum of immunological functions as cytokine/chemokine is termed as Vasoactive Intestinal Peptide (VIP).

https://pubmed.ncbi.nlm.nih.gov/28964637/

The global allergy diagnostics and therapeutics market size was valued at USD 32.06 billion in 2018 and is anticipated to expand further at a strong CAGR of 6.3% over the forecast period.

https://www.google.com/search?q=allergic+diseases+therapeutics+market+size&ie=UTF-8&oe=UTF-8&hl=en-us&client=safari